Cognition Therapeutics, Inc. (CGTX)
NASDAQ: CGTX · Real-Time Price · USD
1.050
-0.030 (-2.78%)
At close: Aug 10, 2026, 4:00 PM EDT
1.059
+0.009 (0.88%)
After-hours: Aug 10, 2026, 7:36 PM EDT

Cognition Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
10.4610.6112.2913.5313.2310.03
Research & Development
26.1437.1941.6837.230.3218.57
Total Operating Expenses
36.647.853.9750.7243.5528.6
Operating Income
-36.6-47.8-53.97-50.72-43.55-28.6
Interest Expense
-0.01-0.01-0.03-0.03-0.03-0.89
Other Non-Operating Income (Expense)
19.8424.3320.0224.9622.1817.78
Total Non-Operating Income (Expense)
19.8324.312024.9422.1516.88
Pretax Income
-16.78-23.49-33.97-25.79-21.4-11.72
Net Income
-16.78-23.49-33.97-25.79-21.4-11.72
Net Income Attributable to Preferred Dividends
-----4.53
Net Income to Common
-16.78-23.49-33.97-25.79-21.4-16.25
Net Income Growth
------
Shares Outstanding (Basic)
87734030245
Shares Outstanding (Diluted)
87734030245
Shares Change
64.46%83.15%32.31%27.03%355.42%921.60%
EPS (Basic)
-0.17-0.32-0.86-0.86-0.91-3.13
EPS (Diluted)
-0.17-0.32-0.86-0.86-0.91-3.13
EPS Growth
------
Free Cash Flow
-17.7-24.59-28.48-16.17-18.7-3.66
Free Cash Flow Growth
------
Free Cash Flow Per Share
-0.20-0.34-0.72-0.54-0.79-0.70
EBITDA
-36.36-47.57-53.7-50.47-43.32-28.51
EBIT
-36.6-47.8-53.97-50.72-43.55-28.6
SEC Filings: 10-K · 10-Q